Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Getinge (ST:GETIb) shares rose more than 7% Friday after the Swedish medical technology firm posted second-quarter results that beat estimates on both adjusted EBITA and earnings per share.
Adjusted EBITA reached SEK 989 million, exceeding the consensus estimate of SEK 921 million by 7.4%.
The adjusted EBITA margin was 12%, 80 basis points higher than the 11.3% consensus. Adjusted earnings per share came in at SEK 2.25, a 14% beat over the consensus forecast of SEK 1.97.
Total (EPA:TTEF) sales for the quarter were in line with expectations. Organic group sales grew 4.1%, ahead of the 2.7% consensus.
Organic order growth was 4.4%, while total orders fell 1.7% short of consensus due to foreign exchange and inorganic impacts.
Acute Care Therapies (ACT) sales were largely in line with expectations. Surgical Workflows (SW) sales missed by 4.4%, while Life Sciences (LS) sales exceeded expectations by 6.5%.
The EBITA beat was primarily driven by the SW division, which saw improved gross margins from productivity gains and a favorable product mix, despite a SEK 23 million foreign exchange headwind. SW also reported strong performance in infection control and digital health solutions.
In LS, growth was driven by sterile transfer, with ongoing rationalizations in sterile sales. ACT showed strength in ventilators and cardiac surgery despite tough year-over-year comparisons, though margins were pressured by tariff and foreign exchange effects.
The company cited a SEK 110 million tariff impact during the quarter and indicated partial success in offsetting these costs through pricing adjustments.
Getinge reiterated its full-year 2025 guidance, projecting organic revenue growth between 2% and 5%. The Q2 performance is expected to lead to roughly 1% upward revisions to full-year 2025 consensus EBITA estimates.
However, both J.P. Morgan and Morgan Stanley (NYSE:MS) noted ongoing earnings volatility across quarters and divisions and said further updates on tariff and foreign exchange impacts are awaited.